Prognostic value of [18F]-fluoro-deoxy-glucose PET/CT, S100 or MIA for assessment of cancer-associated mortality in patients with high risk melanoma

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Essler, Markus ^a   Link, Anna ^a   Belloni, Benedetta ^b   Mirceva, Vesna ^b   Souvatzoglou, Michael ^a   Thaler, Markus ^c   Haller, Bernhard ^b   Hein, Ruediger ^b   Krause, Bernd J ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; MELANOMA INHIBITORY ACTIVITY PROTEIN; PROTEIN S 100; TUMOR PROTEIN; UNCLASSIFIED DRUG; MIA PROTEIN, HUMAN; SCLEROPROTEIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; CYTOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISTANT METASTASIS; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; COMPUTER ASSISTED TOMOGRAPHY; METABOLISM; METHODOLOGY; MIDDLE AGED; MORTALITY; POSITRON EMISSION TOMOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; EXTRACELLULAR MATRIX PROTEINS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM PROTEINS; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; S100 PROTEINS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 80052859025     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024632     Document Type: Article

References (19)

1. Balch CM, Soong SJ, Atkins MB, Buzaid AC, (2009) An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin 54: 131-149.
2. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, et al. (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 20: 6199-6206.
3. Dummer R, Hauschild A, Pentheroudakis G, (2009) Cutaneous malignant melanoma: ESMO clinical recommendations for diagnosis treatment and follow-up. Ann Oncol 20 (supplement 4): 1029-1031.
4. Kirkwood JM, Strawderman MH, Ernstoff M, Smith TJ, Borden EC, et al. (1996) Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14: 7-17.
5. Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome MI, et al. (1999) Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 17: 976-983.
6. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27: 6199-206.
7. Garbe C, Leiter U, Ellwanger U, Blaheta HJ, Meier F, et al. (2003) Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients. Cancer 97: 1737-45.
8. Tarhini AA, Stuckert J, Lee S, Sander C, Kirkwood JM, (2009) Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. J Clin Oncol 27: 38-44.
9. Belhocine TZ, Scott AM, Even-Sapir E, Urbain JL, et al. (2006) Role of nuclear medicine in the management of cutaneous malignant melanoma. J Nucl Med 47: 957-67.
10. Mottaghy FM, Sunderkötter C, Schubert R, Wohlfart P, Blumstein NM, et al. (2007) Direct comparison of [18F]FDG PET/CT with PET alone and with side-by-side PET and CT in patients with malignant melanoma. Eur J Nucl Med Mol Imaging 34: 1355-64.
11. Reinhardt MJ, Joe AY, Jaeger U, Huber A, Matthies A, et al. (2006) Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients. J Clin Oncol 24: 1178-8.
12. Strobel K, Dummer R, Husarik DB, Perez Lago M, Hany TF, et al. (2004) High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases. Radiology 244: 566-74.
13. Pfannenberg C, Aschoff P, Schanz S, Eschmann SM, Plathow C, et al. (2007) Prospective comparison of [18F]-fluoro-deoxy-glucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. Eur J Cancer 43: 557-464.
14. Strobel K, Skalsky J, Kalff V, Baumann K, et al. (2007) Tumour assessment in advanced melanoma: value of FDG-PET/CT in patients with elevated serum S-100B. Eur J Nucl Med Mol Imaging 34: 1366-1375.
15. Pencina M, D'Agostino R, (2004) Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Statist Med 23: 2109-2123.
16. Mazzini GS, Souza DO, Portela LV, (2008) The ischemic heart as an extracerebral source for S100B. Resuscitation 80: 144.
17. Yang JF, Zhang XY, Qi F, et al. (2004) Expression of S100 protein in renal cell carcinoma and its relation with P53. Zhong Nan Da Xue Xue Bao Yi Xue Ban 29: 301-304.
18. Perez RP, Zhang P, Bosserhoff AK, Buettner R, et al. (2000) Expression of melanoma inhibitory activity in melanoma and nonmelanoma tissue specimens. Hum Pathol 2000;31: 1381-1388.
19. Mruck S, Baum RP, Rinne D, Hör G, (1999) Diagnostic accuracy and predictive value of the tumor-associated antigen S100 in malignant melanomas: validation by whole body FDG-PET and conventional diagnostics. Anticancer Res 19 (4A): 2685-90.